Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | THRB | P10828 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 6/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23887092 | 0.79 | CSNK2A2 (0.40) | MAPTTHRBRXFP1CSNK2A2CSNK2B | |
| SCHEMBL23887406 | 0.76 | CCNE2 (0.36) | MAPTTHRBTP53CSNK2A2CSNK2B | |
| SCHEMBL31035619 | 0.74 | PIK3CA (0.34) | MAPTTHRBTP53RXFP1CSNK2A2 | |
| SCHEMBL23887151 | 0.73 | PIK3CA (0.41) | MAPTTP53PIK3CAKMT2AKDM4E | |
| SCHEMBL30307555 | 0.70 | PIK3CA (0.52) | PIK3CA | |
| SCHEMBL24913400 | 0.70 | CSNK2A2 (0.55) | MAPTTP53CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL23887000 | 0.70 | PIK3CA (0.52) | PIK3CA | |
| SCHEMBL23886928 | 0.69 | PIK3CA (0.56) | PIK3CA | |
| SCHEMBL25451398 | 0.68 | CYP1B1 (0.47) | MAPTTHRBATMPIK3CAKMT2A | |
| SCHEMBL23887066 | 0.68 | PRKDC (0.45) | ATMPIK3CAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286960-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11649227-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2023-05-16 | — | — | US | disclosed |
| CN-115956075-A | Allosteric enone inhibitors of phosphoinositide 3-kinases (PI 3 ks) for the treatment of diseases associated with PI3K modulation | 佩特拉制药公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-4126851-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION | Petra Pharma Corporation (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220372023-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2022-11-24 | — | — | US | disclosed |
| WO-2021202964-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION | PETRA PHARMA CORPORATION (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286960-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, AKT3, PIK3R1 | MAPT 809/4885THRB 177/4885TP53 1411/4885 |
| US-20220372023-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, AKT3, PIK3R1 | MAPT 809/4885THRB 177/4885TP53 1411/4885 |
| US-11649227-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, AKT3, PIK3R1 | MAPT 809/4885THRB 177/4885TP53 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.